242 related articles for article (PubMed ID: 10561300)
1. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography.
Schirrmeister H; Guhlmann A; Kotzerke J; Santjohanser C; Kühn T; Kreienberg R; Messer P; Nüssle K; Elsner K; Glatting G; Träger H; Neumaier B; Diederichs C; Reske SN
J Clin Oncol; 1999 Aug; 17(8):2381-9. PubMed ID: 10561300
[TBL] [Abstract][Full Text] [Related]
2. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management.
Hetzel M; Arslandemir C; König HH; Buck AK; Nüssle K; Glatting G; Gabelmann A; Hetzel J; Hombach V; Schirrmeister H
J Bone Miner Res; 2003 Dec; 18(12):2206-14. PubMed ID: 14672356
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic performance of (18)F-fluorodeoxyglucose PET/CT and bone scintigraphy in breast cancer patients with suspected bone metastasis.
Niikura N; Hashimoto J; Kazama T; Koizumi J; Ogiya R; Terao M; Oshitanai R; Morioka T; Tsuda B; Okamura T; Saito Y; Iwaisako K; Iwamoto T; Hayashi N; Imai Y; Tokuda Y
Breast Cancer; 2016 Jul; 23(4):662-7. PubMed ID: 26037335
[TBL] [Abstract][Full Text] [Related]
4. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M
Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330
[TBL] [Abstract][Full Text] [Related]
5. ¹⁸F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers.
Withofs N; Grayet B; Tancredi T; Rorive A; Mella C; Giacomelli F; Mievis F; Aerts J; Waltregny D; Jerusalem G; Hustinx R
Nucl Med Commun; 2011 Mar; 32(3):168-76. PubMed ID: 21076343
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
Qiu ZL; Xue YL; Song HJ; Luo QY
Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer.
Schirrmeister H; Glatting G; Hetzel J; Nüssle K; Arslandemir C; Buck AK; Dziuk K; Gabelmann A; Reske SN; Hetzel M
J Nucl Med; 2001 Dec; 42(12):1800-4. PubMed ID: 11752076
[TBL] [Abstract][Full Text] [Related]
8. Anatomical distribution and sclerotic activity of bone metastases from thyroid cancer assessed with F-18 sodium fluoride positron emission tomography.
Schirrmeister H; Buck A; Guhlmann A; Reske SN
Thyroid; 2001 Jul; 11(7):677-83. PubMed ID: 11484897
[TBL] [Abstract][Full Text] [Related]
9. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
10. A meta-analysis of (18)F-Fluoride positron emission tomography for assessment of metastatic bone tumor.
Tateishi U; Morita S; Taguri M; Shizukuishi K; Minamimoto R; Kawaguchi M; Murano T; Terauchi T; Inoue T; Kim EE
Ann Nucl Med; 2010 Aug; 24(7):523-31. PubMed ID: 20559896
[TBL] [Abstract][Full Text] [Related]
11. Comparison of (18)F-FDG-PET/CT with (99m)Tc-MDP bone scintigraphy for the detection of bone metastases in cancer patients.
Ozülker T; Küçüköz Uzun A; Ozülker F; Ozpaçac T
Nucl Med Commun; 2010 Jun; 31(6):597-603. PubMed ID: 20224457
[TBL] [Abstract][Full Text] [Related]
12. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
Even-Sapir E; Metser U; Mishani E; Lievshitz G; Lerman H; Leibovitch I
J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635
[TBL] [Abstract][Full Text] [Related]
13. A meta-analysis of ¹⁸FDG-PET-CT, ¹⁸FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer.
Qu X; Huang X; Yan W; Wu L; Dai K
Eur J Radiol; 2012 May; 81(5):1007-15. PubMed ID: 21354739
[TBL] [Abstract][Full Text] [Related]
14. Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer.
Hahn S; Heusner T; Kümmel S; Köninger A; Nagarajah J; Müller S; Boy C; Forsting M; Bockisch A; Antoch G; Stahl A
Acta Radiol; 2011 Nov; 52(9):1009-14. PubMed ID: 21969709
[TBL] [Abstract][Full Text] [Related]
15. A meta-analysis of 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with breast cancer.
Liu T; Cheng T; Xu W; Yan WL; Liu J; Yang HL
Skeletal Radiol; 2011 May; 40(5):523-31. PubMed ID: 20495798
[TBL] [Abstract][Full Text] [Related]
16. The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients.
Yen RF; Chen CY; Cheng MF; Wu YW; Shiau YC; Wu K; Hong RL; Yu CJ; Wang KL; Yang RS
Nucl Med Commun; 2010 Jul; 31(7):637-45. PubMed ID: 20389259
[TBL] [Abstract][Full Text] [Related]
17. ¹⁸F-Fluoride PET/CT is highly effective for excluding bone metastases even in patients with equivocal bone scintigraphy.
Bortot DC; Amorim BJ; Oki GC; Gapski SB; Santos AO; Lima MC; Etchebehere EC; Barboza MF; Mengatti J; Ramos CD
Eur J Nucl Med Mol Imaging; 2012 Nov; 39(11):1730-6. PubMed ID: 22949079
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of bone metastases from breast cancer by bone scintigraphy and positron emission tomography/computed tomography imaging.
Pires AO; Borges US; Lopes-Costa PV; Gebrim LH; da Silva BB
Eur J Obstet Gynecol Reprod Biol; 2014 Sep; 180():138-41. PubMed ID: 25037283
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET.
Schirrmeister H; Guhlmann A; Elsner K; Kotzerke J; Glatting G; Rentschler M; Neumaier B; Träger H; Nüssle K; Reske SN
J Nucl Med; 1999 Oct; 40(10):1623-9. PubMed ID: 10520701
[TBL] [Abstract][Full Text] [Related]
20. Bone metastases from breast cancer: associations between morphologic CT patterns and glycolytic activity on PET and bone scintigraphy as well as explorative search for influential factors.
Sugihara T; Koizumi M; Koyama M; Terauchi T; Gomi N; Ito Y; Hatake K; Sata N
Ann Nucl Med; 2017 Dec; 31(10):719-725. PubMed ID: 28864931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
